Strategy analysis

ISPOR Europe 2018 Whitepaper

November 23, 2018

Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Datamonitor Healthcare HIV KOL Interview – US #1

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Japan Pricing and Reimbursement

Pricing and reimbursement processes are closely connected in Japan, with drug pricing largely dependent on innovation. However, achieving premium pricing is difficult, thereby limiting sales potential.

November 4, 2016

Rheumatoid Arthritis Payer Interview – UK

A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Drug Pricing and Market Access KOL Interview

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

February 1, 2016

Non-Small Cell Lung Cancer (NSCLC) KOL Interview – US, East Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.

March 23, 2020

Trends in Gene Therapy

Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects.

October 14, 2016

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Datamonitor Schizophrenia KOL Interview 2

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

February 24, 2016

2015 PCSK9 Inhibitors Pulse

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.

August 19, 2015

Schizophrenia and Bipolar Disorder KOL Interview – Germany

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

ECLIPSE Psoriasis Pulse Survey

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

US Regulatory Issues

Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.

November 2, 2016

HER2+ Breast Cancer KOL Interview – US, West Coast

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include tucatinib, margetuximab, Onzeald, SYD985, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.

March 3, 2020

NASH KOL Insight Interview #2

KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

March 4, 2014

The Contract Biomanufacturing Market Outlook to 2017

$5,000.00

The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.

November 3, 2016

UK Generics and Biosimilars

Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.

November 2, 2016

China Regulatory Update

China has recently completed its 2009–11 healthcare reform. The reform has come at a high cost: although the Ministry of Health intended to invest CNY850bn ($135bn) in the plan, total investment has now exceeded CNY1,100bn ($175bn).

November 4, 2016

Renal Cell Cancer Pricing, Reimbursement, and Access

There is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild.

August 22, 2018

Biosimilars Market Access in the US

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.

October 23, 2015

When Deals Go Wrong: Lessons from Failure

July 12, 2019

Pulmonary Hypertension KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Tyvaso, Tyvaso DPI, Yutrepia, Letairis, Opsumit, Uptravi, Remodulin, Adcirca, sotatercept, INOpulse, and ralinepag.

July 21, 2022

Triple-Negative Breast Cancer KOL Interview – UK

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

Psychiatry KOL Insight Interview

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

January 24, 2014

Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

November 19, 2018

Multiple Sclerosis (MS) KOL Interview – UK, London

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020

Alzheimer’s Disease KOL Interview – US, Northeast

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Multiple Sclerosis (MS) KOL Interview – US, Midwest

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

March 2, 2020